AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16477425 — intervention group
Group type: COMPARATOR
Intervention: Balloon dilatation and the 7.5F flexible ureteroscope (group B; 50 patients)
Number of subjects: 98
Study 14760324 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab infusion for 24 hours
Number of subjects: 404
Study 14760324 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab infusion for 48 hours
Number of subjects: 404
Study 14760324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study 12213991 — intervention group
Group type: EXPERIMENTAL
Intervention: GP IIb/IIIa treatment group
Number of subjects: 196
Study 12213991 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 196
Study 12213991 — intervention group
Group type: COMPARATOR
Intervention: TAMI 7 patients (TIMI 2-3 and TIMI 0-1)
Number of subjects: 196
Study 9644739 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticytokine antibodies (including TNF antibodies)
Number of subjects: 45
Study 9644739 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF antibodies (both in monotherapy and in combination with other anticytokines)
Number of subjects: 45
Study 9644739 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibodies to interferon gamma
Number of subjects: 45
Study 9644739 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibodies to interferon-alpha
Number of subjects: 45
Study 9644739 — intervention group
Group type: COMPARATOR
Intervention: Combined treatment
Number of subjects: 45
Study 8162209 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic Valve Replacement (AVR)
Number of subjects: 225
Study 8162209 — intervention group
Group type: COMPARATOR
Intervention: Mitral Valve Replacement (MVR)
Number of subjects: 225
Study 8162209 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical vs. Bioprosthetic valves in aortic position
Number of subjects: 225
Study 8162209 — intervention group
Group type: EXPERIMENTAL
Intervention: Björk-Shiley vs. Hancock valve in mitral position
Number of subjects: 225
Study 3346412 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mumol/L 15-HETE
Number of subjects: 13
Study 3346412 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mumol/L 15-HETE
Number of subjects: 13
Study 3346412 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 13
Study 3346412 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 ml of 10 mumol/L 15-HEPE
Number of subjects: 13
Study 29338578 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis use
Number of subjects: 372
Study 28388923 — intervention group
Group type: EXPERIMENTAL
Intervention: Peek educational package
Number of subjects: 0
Study 28388923 — intervention group
Group type: COMPARATOR
Intervention: Standard school screening
Number of subjects: 0
Study 26108960 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) in the subthalamic nucleus (STN)
Number of subjects: 21
Study 26108960 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) in the globus pallidus interna (GPi)
Number of subjects: 21
Study 26108960 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa medication
Number of subjects: 21
Study 26108960 — intervention group
Group type: COMPARATOR
Intervention: PD-control group (no intervention)
Number of subjects: 21
Study 23904152 — intervention group
Group type: EXPERIMENTAL
Intervention: Palosuran
Number of subjects: 20
Study 23904152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21089716 — intervention group
Group type: EXPERIMENTAL
Intervention: Early introduction of milk feeds (24-48 hours)
Number of subjects: 404
Study 21089716 — intervention group
Group type: COMPARATOR
Intervention: Late introduction of milk feeds (120-144 hours)
Number of subjects: 404
Study 18192882 — intervention group
Group type: EXPERIMENTAL
Intervention: FLEC regimen (5-fluorouracil 1000 mg/m2, leucovorin 100 mg/m2, epirubicin 60 mg/m2, carboplatin 300 mg/m2 administered every 3 weeks)
Number of subjects: 211
Study 18192882 — intervention group
Group type: EXPERIMENTAL
Intervention: FLEC regimen
Number of subjects: 211
Study 15955037 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual stimulation (8-Hz checkerboard stimulation) during fMRSI
Number of subjects: 10
Study 15955037 — intervention group
Group type: COMPARATOR
Intervention: Darkness (first and fifth measurements)
Number of subjects: 10
Study 12917854 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy (12 psychologic sessions)
Number of subjects: 30
Study 12917854 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psychotherapy sessions)
Number of subjects: 30
Study 12917854 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (G1 and G2)
Number of subjects: 30
Study 12917854 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy (G1)
Number of subjects: 30
Study 10321373 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound screening for abdominal aortic aneurysms in men over 50 and over 65
Number of subjects: 500
Study 7594045 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation (quitters)
Number of subjects: 1026
Study 7594045 — intervention group
Group type: COMPARATOR
Intervention: Continued smoking (smokers)
Number of subjects: 1026
Study 7594045 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation in high risk cohort (no thrombolysis or revascularization)
Number of subjects: 1026
Study 1952874 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of cefprozil once a day for 10 days (n = 72)
Number of subjects: 108
Study 1952874 — intervention group
Group type: COMPARATOR
Intervention: 250 mg of cefaclor three times a day for 10 days (n = 36)
Number of subjects: 108
Study 7291694 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine (0.5 mg/kg IV followed by 2 mg/kg infusion for 2 hours)
Number of subjects: 14
Study 7291694 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine
Number of subjects: 14
Study 7291694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31254051 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injections of anti-VEGF
Number of subjects: 29
Study 28346813 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-dairy protein blend (PB, n = 22)
Number of subjects: 54
Study 28346813 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein isolate (WP, n = 15)
Number of subjects: 54
Study 28346813 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric maltodextrin placebo (MDP, n = 17)
Number of subjects: 54
Study 28346813 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled protein treatments (PB + WP = PRO)
Number of subjects: 54
Study 28346813 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (PB, WP, MDP)
Number of subjects: 54
Study 26414341 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide 200 mg/day
Number of subjects: 1308
Study 26414341 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide 400 mg/day
Number of subjects: 1308
Study 26414341 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide 600 mg/day
Number of subjects: 1308
Study 26414341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1308
Study 26414341 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide (all doses combined) with carbamazepine
Number of subjects: 1308
Study 26414341 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide (all doses combined) with lamotrigine
Number of subjects: 1308
Study 26414341 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide (all doses combined) with levetiracetam
Number of subjects: 1308
Study 26414341 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide
Number of subjects: 1308
Study 22875412 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended follow‐up in the heart failure clinic (HFC) (n = 461)
Number of subjects: 921
Study 22875412 — intervention group
Group type: COMPARATOR
Intervention: Referral back to their general practitioner (GP) (n = 460)
Number of subjects: 921
Study 21035565 — intervention group
Group type: EXPERIMENTAL
Intervention: Home and community-based exercise intervention
Number of subjects: 135
Study 19388923 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet-delivered lidocaine (0.2 mL of buffered 1% lidocaine)
Number of subjects: 197
Study 19388923 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet-delivered placebo (0.2 mL of preservative-free normal saline)
Number of subjects: 197
Study 19388923 — intervention group
Group type: COMPARATOR
Intervention: No device (control group)
Number of subjects: 197
Study 16686553 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (4 x d(‐1) x 5 g creatine monohydrate + 1 g maltodextrin)
Number of subjects: 42
Study 16686553 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 x d(‐1) x 6 g maltodextrin)
Number of subjects: 42
Study 15320673 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (n = 23) - resistance exercises 3 days a week for 12 weeks
Number of subjects: 43
Study 15320673 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (n = 20) - wrist and forearm exercises 3 days a week for 12 weeks
Number of subjects: 43
Study 15320673 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups - 3RM PS and BP measured at 0, 4, 8, and 12 weeks
Number of subjects: 43
Study 11514041 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide, 200 microg (for patients < 11 years) or 400 microg (for patients >= 11 years), administered once daily via Turbuhaler for 3 years
Number of subjects: 0
Study 11514041 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered once daily via Turbuhaler for 3 years
Number of subjects: 0
Study 9031572 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-facilitated intervention
Number of subjects: 36
Study 9031572 — intervention group
Group type: COMPARATOR
Intervention: Lecture discussion group
Number of subjects: 36
Study 8354768 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of amitriptyline and perphenazine
Number of subjects: 37
Study 8354768 — intervention group
Group type: COMPARATOR
Intervention: Amoxapine
Number of subjects: 37
Study 3790749 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-view mammographic screening for breast cancer
Number of subjects: 40318
Study 3790749 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40318
Study 29785635 — intervention group
Group type: EXPERIMENTAL
Intervention: RunKeeper (12-week intervention)
Number of subjects: 32
Study 29785635 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 32
Study 27759405 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride mouth rinse (100 ppm AmF/150 ppm NaF) used by the test group (TG) after tooth brushing.
Number of subjects: 48
Study 27759405 — intervention group
Group type: COMPARATOR
Intervention: No fluoride mouth rinse used by the control group (CG).
Number of subjects: 48
Study 25395906 — intervention group
Group type: EXPERIMENTAL
Intervention: lcRTE (leaf concentrate fortified RTE snack)
Number of subjects: 105
Study 25395906 — intervention group
Group type: COMPARATOR
Intervention: sRTE (standard RTE snack)
Number of subjects: 105
Study 22154038 — intervention group
Group type: EXPERIMENTAL
Intervention: Group CRAFT
Number of subjects: 40
Study 22154038 — intervention group
Group type: COMPARATOR
Intervention: Self‐Directed CRAFT
Number of subjects: 40
Study 22154038 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 40
Study 20206791 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact tablets under fasting conditions
Number of subjects: 32
Study 20206791 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact tablets under fed conditions
Number of subjects: 32
Study 20206791 — intervention group
Group type: COMPARATOR
Intervention: Dissolved tablets under fasting conditions
Number of subjects: 32
Study 20206791 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall safety assessment
Number of subjects: 32
Study 16889053 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipin monotherapy (mean dose 8.9 ± 0.6 mg/day)
Number of subjects: 42
Study 16889053 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril monotherapy (mean dose 17.5 ± 1.4 mg/day)
Number of subjects: 42
Study 16889053 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with amlodipin (6.8 ± 0.7 mg/day) and lisinopril (8.7 ± 0.6 mg/day)
Number of subjects: 42
Study 14578370 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone 20 mg/day for 12 weeks
Number of subjects: 32
Study 14578370 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone discontinued after 12 weeks
Number of subjects: 32
Study 14578370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 11370551 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiochemotherapy (50.4 Gy total dose, 1.8 Gy single dose, 5-FU 1,000 mg/m2/d for 120 hours in weeks 1 and 5, 4 cycles of 5-FU 500 mg/m2/d i.v. bolus)
Number of subjects: 628
Study 11370551 — intervention group
Group type: COMPARATOR
Intervention: Postoperative radiochemotherapy (50.4 Gy total dose, 1.8 Gy single dose, 5-FU 1,000 mg/m2/d for 120 hours in weeks 1 and 5, 4 cycles of 5-FU 500 mg/m2/d i.v. bolus)
Number of subjects: 628
Study 9205035 — intervention group
Group type: EXPERIMENTAL
Intervention: Terumo glide wire
Number of subjects: 0
Study 9205035 — intervention group
Group type: COMPARATOR
Intervention: Standard straight wire
Number of subjects: 0
Study 7692899 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotransfusion of shed blood in patients receiving aprotinin (2 million KIU)
Number of subjects: 40
Study 7692899 — intervention group
Group type: COMPARATOR
Intervention: Control group (no autotransfusion)
Number of subjects: 40
Study 7692899 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients receiving aprotinin
Number of subjects: 40
Study 7692899 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotransfusion in aprotinin-treated patients
Number of subjects: 40
Study 7692899 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving aprotinin)
Number of subjects: 40
Study 3302845 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of ceftriaxone
Number of subjects: 20
Study 3302845 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of ceftriaxone
Number of subjects: 20
Study 30197265 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant plus palonosetron and dexamethasone
Number of subjects: 244
Study 30197265 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus palonosetron and dexamethasone
Number of subjects: 244
Study 30197265 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (after crossover)
Number of subjects: 244
Study 26997378 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 supplementation (100 μg/mL intravenously, two times a week for eight weeks)
Number of subjects: 140
Study 26997378 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 140
Study 26997378 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 supplementation
Number of subjects: 140
Study 24009169 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week singing coaching group (n = 30)
Number of subjects: 89
Study 24009169 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week music listening coaching group (n = 29)
Number of subjects: 89
Study 24009169 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group (n = 30)
Number of subjects: 89
Study 22737716 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/5 ml scopolamine
Number of subjects: 260
Study 22737716 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/5 ml ondansetron
Number of subjects: 260
Study 22737716 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg scopolamine plus 4 mg ondansetron per 5 ml
Number of subjects: 260
Study 22737716 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline 5 ml (control group)
Number of subjects: 260
Study 19643947 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH527123 (50 mg once daily, 4 days)
Number of subjects: 18
Study 19643947 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (50 mg once)
Number of subjects: 18
Study 19643947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 18344386 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 microg budesonide
Number of subjects: 28
Study 18344386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 15879807 — intervention group
Group type: EXPERIMENTAL
Intervention: HM3 lithotriptor
Number of subjects: 264
Study 15879807 — intervention group
Group type: EXPERIMENTAL
Intervention: LSP lithotriptor
Number of subjects: 264
Study 15879807 — intervention group
Group type: EXPERIMENTAL
Intervention: SLX lithotriptor
Number of subjects: 264
Study 15207942 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 23
Study 15207942 — intervention group
Group type: EXPERIMENTAL
Intervention: Light therapy
Number of subjects: 23
Study 15207942 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CBT and light therapy
Number of subjects: 23
Study 15207942 — intervention group
Group type: COMPARATOR
Intervention: Light therapy alone
Number of subjects: 23
Study 11511559 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg followed by 30 mg four times daily
Number of subjects: 414
Study 11511559 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 2 g followed by 1 g four times daily
Number of subjects: 414
Study 11511559 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs (lansoprazole and tranexamic acid)
Number of subjects: 414
Study 11511559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 414
Study 9255202 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized recombinant human deoxyribonuclease (rhDNase) 10 mg twice a day for 14 days, followed by a 14-day washout period for a total of 6 treatment cycles.
Number of subjects: 184
Study 9255202 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized recombinant human deoxyribonuclease (rhDNase)
Number of subjects: 184
Study 8487669 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet rich in stearic acid (C18:0)
Number of subjects: 15
Study 8487669 — intervention group
Group type: COMPARATOR
Intervention: Diet high in lauric and myristic acid (C12:0, C14:0)
Number of subjects: 15
Study 3694448 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐discrepant priming
Number of subjects: 0
Study 3694448 — intervention group
Group type: COMPARATOR
Intervention: self‐relevant/nondiscrepant priming
Number of subjects: 0
Study 3694448 — intervention group
Group type: COMPARATOR
Intervention: yoked priming
Number of subjects: 0
Study 29558034 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Sinaki exercises
Number of subjects: 91
Study 29558034 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic walking
Number of subjects: 91
Study 29558034 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of modified Sinaki exercises and Nordic walking
Number of subjects: 91
Study 29558034 — intervention group
Group type: COMPARATOR
Intervention: Control group (pharmacological treatment only)
Number of subjects: 91
Study 28498181 — intervention group
Group type: EXPERIMENTAL
Intervention: MIP clinics
Number of subjects: 1350
Study 28498181 — intervention group
Group type: EXPERIMENTAL
Intervention: MIP + SMS
Number of subjects: 1350
Study 28498181 — intervention group
Group type: COMPARATOR
Intervention: SOC
Number of subjects: 1350
Study 26245728 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium stimulation setting (62% PMT)
Number of subjects: 7
Study 26245728 — intervention group
Group type: COMPARATOR
Intervention: High stimulation setting (72% PMT)
Number of subjects: 7
Study 26245728 — intervention group
Group type: COMPARATOR
Intervention: Low stimulation setting (52% PMT)
Number of subjects: 7
Study 23388687 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus ointment once a week
Number of subjects: 75
Study 23388687 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus ointment twice a week
Number of subjects: 75
Study 23388687 — intervention group
Group type: COMPARATOR
Intervention: Vehicle twice a week
Number of subjects: 75
Study 21295802 — intervention group
Group type: EXPERIMENTAL
Intervention: DEB-TACE
Number of subjects: 72
Study 21295802 — intervention group
Group type: COMPARATOR
Intervention: TACE
Number of subjects: 72
Study 19241920 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative urinary trypsinogen‐2 measurement in Group 1 (acute pancreatitis)
Number of subjects: 99
Study 19241920 — intervention group
Group type: COMPARATOR
Intervention: Qualitative urinary trypsinogen‐2 measurement in Group 2 (no acute pancreatitis)
Number of subjects: 99
Study 17142206 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam (OM) 0.4 mg/kg mixed with cherry juice
Number of subjects: 80
Study 17142206 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (INM) 0.2 mg/kg as drops
Number of subjects: 80
Study 17142206 — intervention group
Group type: COMPARATOR
Intervention: Control group (oral cherry juice or intranasal serum physiologic)
Number of subjects: 80
Study 14610441 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized daily schedule
Number of subjects: 0
Study 14610441 — intervention group
Group type: COMPARATOR
Intervention: Historic controls
Number of subjects: 0
Study 10910832 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil combined with intrathecal morphine (R group)
Number of subjects: 40
Study 10910832 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil (S group)
Number of subjects: 40
Study 8929583 — intervention group
Group type: EXPERIMENTAL
Intervention: Cr (0.5 g x kg‐1 x day‐1)
Number of subjects: 9
Study 8929583 — intervention group
Group type: EXPERIMENTAL
Intervention: Cr (0.5 g x kg‐1 x day‐1) + C (5 mg x kg‐1 x day‐1)
Number of subjects: 9
Study 8929583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 1533376 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin acetate 900 micrograms/d intranasally (IN)
Number of subjects: 97
Study 1533376 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin 400 micrograms/d IN
Number of subjects: 97
Study 1533376 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol 400 mg/d orally
Number of subjects: 97
Study 3912619 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF + tamoxifen (T)
Number of subjects: 263